Finoriq research workspace
Aktis Oncology, Inc. (AKTS) SEC Filings & Filing Highlights
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development. Review AKTS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
- Company
- Aktis Oncology, Inc. (AKTS)
- Ticker
- AKTS
- Market Cap
- $1.3B
- Latest Price
- $23.81
- Industry
- Biotech & Pharma
Aktis Oncology, Inc. (AKTS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Aktis Oncology, Inc. (AKTS).
| Event | Form | Date |
|---|---|---|
| Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026Aktis Oncology Reports Financial Results and Business Highlights For First Quarter 2026 | 8-K2.02 | 2026-05-11 |
| Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its...Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors | 8-K7.01 | 2026-04-16 |
| Appointment of Glenn Gormley to the Board of Directors On April 15, 2026, the board of director...Appointment of Glenn Gormley to the Board of Directors On April 15, 2026, the board of directors (the “Board”) of Aktis Oncology, Inc. (the... | 8-K5.02 | 2026-04-16 |
| Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 an...Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 20... | 8-K2.02 | 2026-03-30 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-01-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.